Trial · NCT07897565
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | ORR by RECIST v1.1 | Up to 39 months. | Objective response rate (ORR) is defined as complete response (CR) rate + partial response (PR) rate according to RECIST v1.1. |
| Secondary | DCR by RECIST v1.1 | Up to 39 months. | Disease control rate (DCR) is defined as complete response (CR) rate + partial response (PR) rate + stable disease (SD) rate according to RECIST v1.1. |
| Secondary | DOR by RECIST v1.1 | From the date of first documented complete response (CR) or partial response (PR) ,whichever came first, until the date of first documented disease progression, assessed up to 39 months. | Duration of response (DOR) is defined as time from the first complete response (CR) or partial response (PR) to disease progression according to RECIST v1.1. |
| Secondary | TTP by RECIST v1.1 | From the date of enrollment until the date of first documented disease progression, assessed up to 39 months. | Time to progression (TTP) is defined as time from enrollment to disease progression according to RECIST v1.1. |
| Secondary | PFS by RECIST v1.1 | From the date of enrollment until the date of first documented disease progression or death from any cause, whichever came first, assessed up to 39 months. | Progression-free survival (PFS) is defined as time from enrollment to disease progression assessed (according to RECIST v1.1) or death from any cause. |
| Secondary | OS | From the date of enrollment until the date of death from any cause, assessed up to 39 months. | Overall survival (OS) is defined as time from enrollment to death from any cause. |
| Secondary | ORR by iRECIST | Up to 39 months. | Objective response rate (ORR) is defined as complete response (CR) rate + partial response (PR) rate according to iRECIST. |
| Secondary | QoL assessment 1 | Up to 25 months. | Impact on quality of life (Quality of Life Scores) assessed by EORTC QLQ-C30 |
| Secondary | QoL assessment 2 | Up to 25 months. | Impact on quality of life (Quality of Life Scores) assessed by EORTC QLQ-BIL21 |
| Other | Safety assessment | Up to 39 months. | Number of Participants With Adverse Events as Assessed by CTCAE v6.0 |
| Other | Number of participants with Exploratory markers | Up to 39 months. | Predictive biomarker status in participants as assessed by sequencing-based analysis |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07897565/registered